AMSTERDAM (dpa-AFX) - Dutch consumer electronics giant Koninklijke Philips Electronics NV (PHGFF.PK, PHG) has received 510(k) clearance from the U.S. Food and Drug Administration to market its precision planning application for Transcatheter Aortic-Valve Implantation or TAVI treatments. Through 3D imaging, the Philips TAVI application provides interventionalists with pre-procedural, high-precision positioning to treat aortic stenosis ailments.
The TAVI planning application provides planes and panel measurements for precisely placing TAVI devices to manage the risk of under- or oversizing of a TAVI device via. advanced computed tomography imaging.
The TAVI technology received FDA approval in 2011.
Copyright RTT News/dpa-AFX
© 2014 AFX News
